New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
04:55 EDTILMN, ILMN, AET, AET, AMGN, AMGN, NVS, NVS, ECYT, ECYT, CELG, CELG, LIFE, LIFE, OMED, OMED, MRK, MRK, CERN, CERN, TROV, TROV, UNH, UNHPersonalized Medicine World Conference to hold a conference
PMWC 2014 Silicon Valley is being held in Mountain View, California on January 26-28.
News For ILMN;TROV;CERN;MRK;OMED;LIFE;CELG;ECYT;NVS;AMGN;AET;UNH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
June 25, 2015
09:27 EDTILMNLeerink life science tools analyst holds an analyst/industry conference call
Life Science Tools and Diagnostics Dan Leonard, along with Dr. Paul Robson and Dr. Peter Kuhn, discuss the demand for Fluidigm's single cell prep products, including the impact to Biomark and the utility of CyTOF on an Analyst/Industry conference call to be held on July 1 at 2 pm.
09:21 EDTILMNBioMed Realty leases build-to-suit laboratory in Cambridge to Illumina
BioMed Realty (BMR) announced that Illumina ILMN) has signed a 20-year lease for a 155,000 square foot new and innovative scientific research building in Cambridge, England. BioMed Realty acquired the land for the project from The Welding Institute under a long term ground lease, enlarging BioMed Realty's Granta Park campus in Cambridge, England.
June 24, 2015
17:57 EDTUNH, AETWall Street applauds Senate giving go-ahead for 'fast track' trade powers
Subscribe for More Information
10:00 EDTUNH, AETOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:07 EDTMRKCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
07:56 EDTAMGNAmgen management to meet with Evercore ISI
Subscribe for More Information
06:36 EDTAETAetna initiated with a Sector Perform at RBC Capital
Subscribe for More Information
06:35 EDTUNHUnitedHealth initiated with an Outperform at RBC Capital
Subscribe for More Information
05:42 EDTUNHCatamaran downgraded to Neutral from Buy at UBS
UBS downgraded Catamaran (CTRX) to Neutral saying the stock new fully reflects the UnitedHealth (UNH) takeover deal terms. UnitedHealth management in recent meetings expressed confidence that its pending $61.50 per share purchase of Catamaran will still close in the second half of 2015, UBS tells investors.
June 23, 2015
07:44 EDTAETHumana takeover looks unlikely below $210/share, says Leerink
Subscribe for More Information
07:25 EDTUNH, AMGNPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
June 22, 2015
18:56 EDTAETCigna/Anthem deal could leave Humana with Aetna as only suitor, Bloomberg says
Subscribe for More Information
08:16 EDTAETAnthem, Cigna deal would be negative for Catamaran, says Leerink
Subscribe for More Information
07:54 EDTAETAnthem, Cigna deal likely to be consummated, says Leerink
Subscribe for More Information
07:16 EDTAETAnthem should be bought after Cigna offer, says Stifel
After Anthem, (ANTM) offered to buy Cigna (CI) and the latter company rejected the bid, Stifel estimates that the deal would have been 10% accretive for Anthem in the first year and 20% accretive in the second year. The firm thinks that accretion from the deal will probably be higher than expected. It also recommends buying Aetna (AET) as it believes that the Anthem offer suggests that Aetna will benefit more than expected from its own deal. The firm is cautious on Humana (HUM), saying that it may lose two potential buyers in Anthem and Cigna, while Humana may retreat if Aetna does not acquire the company quickly.
07:05 EDTCERNCerner management to meet with FBR Capital
Subscribe for More Information
06:51 EDTUNH, AETHealth insurer tie-ups could cut competition, WSJ reports
Subscribe for More Information
06:37 EDTUNH, AETHealth insurers may change policies based on King v. Burwell ruling, NYT says
Subscribe for More Information
June 21, 2015
16:03 EDTUNH, AETAetna makes offer to acquire Humana, WSJ says
Subscribe for More Information
13:14 EDTMRKMerck shares could return 25%, Barron's says
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use